Understand the influence of COVID-19 on the
Alpha 1 Antitrypsin Deficiency Treatment Market Size with our analysts monitoring the situation across the globe.
Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called "additional therapies"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).
The global Alpha 1 Antitrypsin Deficiency Treatment market is valued at 1190 million US$ in 2018 and will reach 2560 million US$ by the end of 2025, growing at a CAGR of 10.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Alpha 1 Antitrypsin Deficiency Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Alpha 1 Antitrypsin Deficiency Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alpha 1 Antitrypsin Deficiency Treatment in these regions.
This research report categorizes the global Alpha 1 Antitrypsin Deficiency Treatment market by top players/brands, region, type and end user. This report also studies the global Alpha 1 Antitrypsin Deficiency Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Teva Pharmaceutical Industries
Applied Genetic Technologies
Arrowhead Research Corporation
ProMetic Life Sciences
Market size by Product
Market size by End User
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global Alpha 1 Antitrypsin Deficiency Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Alpha 1 Antitrypsin Deficiency Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Alpha 1 Antitrypsin Deficiency Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Alpha 1 Antitrypsin Deficiency Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Alpha 1 Antitrypsin Deficiency Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alpha 1 Antitrypsin Deficiency Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.